IsoRay Inc ISR:NYSE American

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/11/22 EDT
0.38quote price arrow up+0.01 (+4.05%)
Volume
6,505
Close
0.37UNCH (UNCH)
Volume
386,962
52 week range
0.25 - 0.75
Loading...
  • Open0.35
  • Day High0.38
  • Day Low0.35
  • Prev Close0.36
  • 52 Week High0.75
  • 52 Week High Date09/14/21
  • 52 Week Low0.25
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap52.55M
  • Shares Out142.04M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.92
  • YTD % Change-4.59

KEY STATS

  • Open0.35
  • Day High0.38
  • Day Low0.35
  • Prev Close0.36
  • 52 Week High0.75
  • 52 Week High Date09/14/21
  • 52 Week Low0.25
  • 52 Week Low Date05/12/22
  • Market Cap52.55M
  • Shares Out142.04M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.92
  • YTD % Change-4.59

RATIOS/PROFITABILITY

  • EPS (TTM)-0.04
  • P/E (TTM)-8.39
  • Fwd P/E (NTM)-10.00
  • EBITDA (TTM)-6.113M
  • ROE (TTM)-9.53%
  • Revenue (TTM)11.00M
  • Gross Margin (TTM)45.78%
  • Net Margin (TTM)-56.86%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date09/19/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On IsoRay Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy...
Michael Mccormick
Independent Chairman of the Board
Lori Woods
Chief Executive Officer, Director
Jennifer Streeter
Chief Operating Officer, Vice President - Human Resources
Mark Austin
Co- Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Corporate Controller, Corporate Secretary
Jonathan Hunt
Chief Financial Officer, Co-Principal Financial Officer
Address
Suite 106, 350 Hills Street,
Richland, WA
99354
United States

Top Peers

SYMBOLLASTCHG%CHG
EYEN
Eyenovia Inc
1.66UNCHUNCH
PHAS
PhaseBio Pharmaceuticals Inc
1.21UNCHUNCH
CBIO
Catalyst Biosciences Inc
1.86UNCHUNCH
ALGS
Aligos Therapeutics Inc
1.40UNCHUNCH
ORTX
Orchard Therapeutics PLC
0.60UNCHUNCH